Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic CMT NGS Panel

Transgenomic has launched its CMT NGS Panel for the diagnosis of Charcot-Marie-Tooth peripheral neuropathies. CMT neuropathies comprise a group of genetic disorders that affect peripheral nerves and are considered part of the muscular dystrophy family. There is considerable varability in the large number of genetic mutations associated with CMT, so Transgenomic designed its panel to test for all 36 reported CMT disease-causing genes, the company said. However, studies have also shown that a majority of patients have mutations in a single gene, making a sequential approach to CMT testing economical and efficient, the company noted. As such, Transgenomic is also offering CMT Reflex Analysis, which comprises first-tier testing of commonly occurring PMP22 deletions/duplications. If these come back negative, then all 36 reported CMT dosease-causing genes are sequenced, Transgenomic said.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.